Kappa immunoglobulin promoters and enhancers display developmentally controlled interactions.
about
Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.A new hypersensitive site, HS10, and the enhancers, E3' and Ed, differentially regulate Igκ gene expressionSelective synergy of immunoglobulin enhancer elements in B-cell development: a characteristic of kappa light chain enhancers, but not heavy chain enhancersAn AP1 binding site upstream of the kappa immunoglobulin intron enhancer binds inducible factors and contributes to expressionA developmentally modulated chromatin structure at the mouse immunoglobulin kappa 3' enhancer.A defective Vkappa A2 allele in Navajos which may play a role in increased susceptibility to haemophilus influenzae type b diseaseDevelopmental regulation of the kappa locus involves both positive and negative sequence elements in the 3' enhancer that affect synergy with the intron enhancer.Regulation of V(D)J recombination by transcriptional promoters.Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domainsImmunoglobulin kappa enhancers are differentially regulated at the level of chromatin structure.Octamer independent activation of transcription from the kappa immunoglobulin germline promoter.A potential role for Elf-1 in terminal transferase gene regulationCoordinate transcription and V(D)J recombination of the kappa immunoglobulin light-chain locus: NF-kappaB-dependent and -independent pathways of activation.Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
P2860
Q34380431-C4CBF1D3-AF80-4148-9288-072915057808Q35803016-C397A159-D088-4D88-8248-BAF814CCF176Q35869787-A53A5C75-C66E-4404-89C7-A1D8D5B52DC3Q35874340-5458EE0A-CB4B-4B3A-BDC2-44AA83F507FDQ36560382-0E749AAC-022C-43AF-9486-FEAEDAF4F109Q37354966-BA622807-A6E3-4CDB-A9D8-340D123990A6Q38329021-66EDC2A6-CC19-4A1A-9272-D9F7CDA02E97Q39445192-44E1FD87-B07A-426F-862E-80E97668E09BQ39575556-532F4F6D-3AB5-49EB-9782-74A7B38B61EDQ39662713-524C7DD2-BDAD-4A41-A6C8-4C275F2E9B6DQ39718297-BDF819A8-3683-45FA-9655-958E64E5C6D7Q40020202-665F0DC4-9F1F-41B5-9280-81E1E0B47130Q40022474-450F12C8-0A93-4840-B3C4-7AD6FC2D7D9AQ41121076-962F50D8-FF8A-4813-BF3D-E5DEBB56C003Q43059808-62601ACE-A67B-4C36-9261-E1F53CCAA8AC
P2860
Kappa immunoglobulin promoters and enhancers display developmentally controlled interactions.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Kappa immunoglobulin promoters ...... tally controlled interactions.
@en
type
label
Kappa immunoglobulin promoters ...... tally controlled interactions.
@en
prefLabel
Kappa immunoglobulin promoters ...... tally controlled interactions.
@en
P2860
P356
P1476
Kappa immunoglobulin promoters ...... tally controlled interactions.
@en
P2093
P2860
P304
P356
10.1093/NAR/21.21.4941
P577
1993-10-01T00:00:00Z